In a study by Nasioudis et al,22the authors were unable to verify that CTX can prolong survival time in patients with stages II–IV carcinoids, although another study noted that the Ki‐67 proliferation index may aid in the selection of patients likely to benefit from CTX.25 The gene discussed is MKI67; the disease is carcinoid tumor.